Bristol-Myers Squibb Company
) and partner
) recently presented data on their oncology candidate,
elotuzumab, from a phase II study. Results were presented at the
annual meeting of the European Hematology Association held in
ABBVIE INC (ABBV): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.
The randomized, open-label study evaluated the candidate,
combined with a low-dose dexamethasone and
) Revlimid (lenalidomide), in treatment-experienced multiple
myeloma (MM) patients at two doses- 10 mg/kg and 20 mg/kg.
Data from the study revealed that the median progression-free
survival (PFS: the time without disease worsening or death) was
33 months after 20.8 months of follow up in the 10 mg/kg arm.
Moreover, the objective response rate (ORR) was observed to be
92% in the 10 mg/kg arm. The median PFS and ORR were found to be
18 months (after 17.1 months of follow up) and 76%, respectively,
for patients treated with the 20 mg/kg dosage of elotuzumab. The
safety profile of the candidate was found to be consistent with
those revealed by the earlier studies.
Apart from the above phase II study, Bristol-Myers/AbbVie are
also evaluating elotuzumab in other studies. The combination of
elotuzumab (10 mg/kg), Revlimid and low-dose dexamethasone is
being evaluated in two phase III studies (ELOQUENT-1 and
ELOQUENT-2). Moreover, a combination of Velcade (bortezomib) and
dexamethasone with or without elotuzumab is also being evaluated
in a phase II study in patients suffering from
relapsed/refractory multiple myeloma.
Successful development and subsequent commercialization of
elotuzumab would boost the top lines of both companies since the
MM market offers significant commercial potential.
AbbVie as well as Bristol-Myers currently carry a Zacks Rank #3
(Hold). Companies such as
) currently look more attractive with a Zacks Rank #1 (Strong